Most Read Articles
3 days ago
Nintedanib does not appear to improve survival in heavily pretreated patients with metastatic colorectal cancer (CRC), according to data from the phase III LUME-Colon 1 trial.
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Podcast: Prof Gary Raskob speaks on dalteparin vs low-molecular-weight heparin/edoxaban for venous thromboembolism

21 Dec 2017
Professor Gary Raskob from the College of Public Health, University of Oklahoma, Oklahoma City, US speaks about the efficacy and safety of dalteparin vs low-molecular-weight heparin/edoxaban for venous thromboembolism in patients with cancer.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Nintedanib does not appear to improve survival in heavily pretreated patients with metastatic colorectal cancer (CRC), according to data from the phase III LUME-Colon 1 trial.
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.